Next-Generation Imaging
Next-Generation Imaging
Emily MenendezASCO 2023 | June 3, 2023
The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress.
Read More
Zachary BessetteASCO 2023 | June 2, 2023
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
Emily MenendezNext-Generation Imaging | May 30, 2023
POSLUMA is a diagnostic imaging agent for the PET detection of PSMA-positive lesions in patients with prostate cancer.
Emily MenendezNext-Generation Imaging | May 11, 2023
A newly developed prognostic risk score had a good model fit for predicting OS in internal and external validation cohorts.
Emily MenendezAUA 2023 | April 28, 2023
When testing interaction with the use of MDT, patients with positive PSMA PET not receiving MDT had a higher risk of CR.
Leah LawrenceProstate Cancer | April 19, 2023
Several physicians highlight the newest data on radiation for metastatic prostate cancer and its role moving forward.
Cora N. Sternberg, MDnmCRPC | April 11, 2023
Dr. Sternberg shares the therapeutic options for nmCRPC patients, how stage at diagnosis impacts these options, and more.
Emily MenendezRLT-PSMA | April 7, 2023
A study evaluated patients with mCRPC who received 177Lu-PSMA-617 to determine OS and PSA-PFS rates.
Emily MenendezNext-Generation Imaging | March 17, 2023
Researchers used determined if an increase in ACM risk existed when sRT was delivered above a prespecified PSA level.
Scott Tagawa, MD, MS, FACPNext-Generation Imaging | February 22, 2023
Scott Tagawa, MD, MS, FACP, explains the distinct ways in which PSMA imaging compares to standard cross-sectional imaging.
David Nanus, MDASCO GU Symposium 2023 | February 17, 2023
David Nanus, MD, details the ways in which PSMA PET varies in guidelines and is used to stage localized prostate cancer.
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
A cohort analysis found that PSMA PET at baseline, before pRT, or before sRT may predict from pelvic radiotherapy.
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
A new analysis demonstrates “excellent potential” for a radiomic-based diagnostic tool to identify PC recurrence risk.
Alex Pozdnyakov, MDNext-Generation Imaging | February 8, 2023
Alex Pozdnyakov, MD, explains the current utility and potential application of PSMA PET imaging in prostate cancer.
Matthew Deek, MDNext-Generation Imaging | January 31, 2023
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
Gary Ulaner, MD, PhD, FACNMNext-Generation Imaging | January 24, 2023
Dr. Ulaner details the current application and capabilities of molecular imaging in prostate cancer.
Tomi Jun, MDExpert Interviews | January 5, 2023
Tomi Jun, MD, shares the clinical actionability and utilization of NGS for prostate cancer in a changing treatment landscape.
Zachary BessetteNext-Generation Imaging | December 22, 2022
The Ga-PSMA-11 and Ga-P16-093 PSMA-PET tracers are useful tools for surgical guidance in prostate cancer.
Emily MenendezNext-Generation Imaging | December 8, 2022
iQuest is the first AI-powered platform of its kind to aid in the development of personalized prostate cancer care plans.